How These Healthcare Stocks are Faring? -- GlaxoSmithKline, Shire, Pacira Pharma, and Supernus Pharma

Thursday, February 16, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, February 16, 2017 /PRNewswire/ --

On Wednesday, February 15, 2017, the NASDAQ

Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell, continuing the bullish streak that started last week. Seven out of nine sectors ended Wednesday's trading session in bullish territories. Taking into consideration
yesterday's market sentiment, assessed the following Healthcare equities this morning: GlaxoSmithKline PLC (NYSE: GSK), Shire PLC (NASDAQ: SHPG), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN). Download the free research reports on these stocks today:


Brentford, the UK headquartered GlaxoSmithKline PLC's stock finished Wednesday's session 1.15% higher at $40.57 with a total volume of 4.07 million shares traded. Over the last one month and the previous three months, GlaxoSmithKline's shares have advanced 3.23% and 4.08%, respectively. Furthermore, the stock has gained 6.74% in the past one year. The Company's shares are trading above its 50-day moving average by 4.57%. Shares of GlaxoSmithKline, which creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide, are trading at a PE ratio of 87.81. The stock has a Relative Strength Index (RSI) of 71.57. See our free and comprehensive research report on GSK at:


On Wednesday, shares in Dublin, Ireland headquartered Shire PLC ended the session 1.09% higher at $174.20 with a total volume of 1.58 million shares traded. Shire's shares have advanced 3.59% in the last one month and 3.37% in the previous one year. Shares of the Company, which together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products, are trading at a PE ratio of 65.56. The stock is trading 2.76% above its 50-day moving average. Moreover, the Company's shares have an RSI of 60.56. SHPG free research report PDF is just a click away at:

Pacira Pharma  

On Wednesday, shares in Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc. recorded a trading volume of 628,889 shares. The stock ended the day 3.52% higher at $44.15. Pacira Pharma's stock has gained 11.77% in the last one month and 17.73% in the previous three months. The Company is trading above its 50-day and 200-day moving averages by 21.03% and 14.90%, respectively. Furthermore, shares of Pacira Pharma, which develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have an RSI of 68.85. Sign up for your complimentary report on PCRX at:

Supernus Pharma  

Rockville, Maryland-based Supernus Pharmaceuticals Inc.'s stock edged 0.76% higher, to close the day at $26.60. The stock recorded a trading volume of 316,568 shares. Supernus Pharma's shares have surged 11.76% in the last one month, 11.30% in the previous three months, and 99.25% in the past one year. The Company's shares are trading 6.50% and 20.69% above its 50-day and 200-day moving averages, respectively. Shares of the Company, which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the US, are trading at a PE ratio of 16.48. Additionally, the stock has an RSI of 58.32. Register for free on and download the latest research report on SUPN at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store